PE20141049A1 - Composicion farmaceutica antihipertensiva - Google Patents
Composicion farmaceutica antihipertensivaInfo
- Publication number
- PE20141049A1 PE20141049A1 PE2013002274A PE2013002274A PE20141049A1 PE 20141049 A1 PE20141049 A1 PE 20141049A1 PE 2013002274 A PE2013002274 A PE 2013002274A PE 2013002274 A PE2013002274 A PE 2013002274A PE 20141049 A1 PE20141049 A1 PE 20141049A1
- Authority
- PE
- Peru
- Prior art keywords
- same
- pharmaceutical composition
- solvate
- hydrate
- pharmaceutically acceptable
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000003276 anti-hypertensive effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 102000008873 Angiotensin II receptor Human genes 0.000 abstract 1
- 108050000824 Angiotensin II receptor Proteins 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 239000005475 Fimasartan Substances 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 229960000528 amlodipine Drugs 0.000 abstract 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- AMEROGPZOLAFBN-UHFFFAOYSA-N fimasartan Chemical compound CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 AMEROGPZOLAFBN-UHFFFAOYSA-N 0.000 abstract 1
- 229960003489 fimasartan Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003087 receptor blocking agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
REFERIDO A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) FIMASARTAN, UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, UN SOLVATO O UN HIDRATO DEL MISMO COMO UN BLOQUEADOR DEL RECEPTOR DE ANGIOTENSINA II, EN UNA CANTIDAD ENTRE 0.5 HASTA 240mg; Y B) AMLODIPINA, UN ISOMERO DE LA MISMA, UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, UN SOLVATO, O UN HIDRATO DE LA MISMA COMO UN BLOQUEADOR DEL CANAL DE CALCIO, EN UNA CANTIDAD ENTRE 0.1 HASTA 20mg. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA HIPERTENSION, DEFICIENCIA CARDIACA, APOPLEJIA CEREBRAL, ARTERIOSCLEROSIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110033856 | 2011-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141049A1 true PE20141049A1 (es) | 2014-09-05 |
Family
ID=47006840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002274A PE20141049A1 (es) | 2011-04-12 | 2011-08-08 | Composicion farmaceutica antihipertensiva |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8765776B2 (es) |
| JP (1) | JP5782178B2 (es) |
| AU (1) | AU2011365756B2 (es) |
| BR (1) | BR112013025222B8 (es) |
| CA (1) | CA2832758C (es) |
| CL (1) | CL2013002905A1 (es) |
| CO (1) | CO6821940A2 (es) |
| CR (1) | CR20130526A (es) |
| EA (1) | EA024096B1 (es) |
| EC (1) | ECSP13012962A (es) |
| GT (1) | GT201300241A (es) |
| MA (1) | MA35107B1 (es) |
| MX (1) | MX341450B (es) |
| MY (1) | MY160432A (es) |
| NI (1) | NI201300106A (es) |
| PE (1) | PE20141049A1 (es) |
| SG (1) | SG194162A1 (es) |
| UA (1) | UA110244C2 (es) |
| WO (1) | WO2012141385A1 (es) |
| ZA (1) | ZA201307593B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG194162A1 (en) | 2011-04-12 | 2013-11-29 | Boryung Pharm | Antihypertensive pharmaceutical composition |
| KR101490329B1 (ko) * | 2012-10-12 | 2015-02-04 | 보령제약 주식회사 | 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물 |
| KR20140096514A (ko) * | 2013-01-28 | 2014-08-06 | 보령제약 주식회사 | 암 예방 또는 치료용 조성물 |
| MX368148B (es) * | 2013-03-14 | 2019-09-20 | Boryung Pharm | Farmaco de combinacion farmaceutica. |
| KR20150041223A (ko) * | 2013-10-04 | 2015-04-16 | 보령제약 주식회사 | 피마살탄을 포함하는 허혈성 뇌질환 예방 또는 치료용 약학적 조성물 |
| CN105395552A (zh) * | 2014-09-05 | 2016-03-16 | 南京华威医药科技开发有限公司 | 一种含非马沙坦及其盐的固体制剂 |
| KR101545268B1 (ko) * | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
| WO2017091041A1 (ko) * | 2015-11-26 | 2017-06-01 | 보령제약 주식회사 | 피마살탄의 신규 염 |
| US11452690B1 (en) | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
| CN112704667A (zh) * | 2021-02-24 | 2021-04-27 | 施慧达药业集团(吉林)有限公司 | 含苯磺酸左氨氯地平水合物的组合物及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
| CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| EP0733366B1 (en) | 1988-01-07 | 1998-04-01 | E.I. Du Pont De Nemours And Company | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics |
| KR100300566B1 (ko) | 1994-09-17 | 2001-11-22 | 조생현 | 피리미디논유도체와그의제조방법및용도 |
| KR19990081093A (ko) * | 1998-04-25 | 1999-11-15 | 조생현 | 피리미디논 화합물, 이를 함유하는 약제학적 조성물 및 이의제조방법 |
| EP2322174B1 (en) | 1998-07-10 | 2015-09-23 | Novartis Pharma AG | Combined use of valsartan and calcium channel blockers for therapeutic purposes |
| FR2783422A1 (fr) | 1998-09-21 | 2000-03-24 | Sanofi Sa | Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire |
| KR100617953B1 (ko) | 2000-03-23 | 2006-08-30 | 보령제약 주식회사 | 피리미디논 화합물 및 이의 염의 제조방법 |
| JP4268871B2 (ja) * | 2001-09-21 | 2009-05-27 | ボリョン ファーマシューティカル カンパニー リミテッド | ピリミジノン化合物及びその薬剤として許容される塩の製造方法 |
| KR100521980B1 (ko) | 2002-10-10 | 2005-10-17 | 보령제약 주식회사 | 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법 |
| US20080279942A1 (en) * | 2005-06-27 | 2008-11-13 | Takeshi Hamaura | Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker |
| KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
| KR20100048137A (ko) | 2008-10-30 | 2010-05-11 | 현대약품 주식회사 | 혈압 강하용 약학 조성물 |
| KR101058284B1 (ko) | 2010-01-22 | 2011-08-22 | 보령제약 주식회사 | 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법 |
| SG194162A1 (en) | 2011-04-12 | 2013-11-29 | Boryung Pharm | Antihypertensive pharmaceutical composition |
-
2011
- 2011-08-08 SG SG2013075585A patent/SG194162A1/en unknown
- 2011-08-08 PE PE2013002274A patent/PE20141049A1/es active IP Right Grant
- 2011-08-08 JP JP2014505053A patent/JP5782178B2/ja not_active Expired - Fee Related
- 2011-08-08 BR BR112013025222A patent/BR112013025222B8/pt active IP Right Grant
- 2011-08-08 AU AU2011365756A patent/AU2011365756B2/en not_active Ceased
- 2011-08-08 CA CA2832758A patent/CA2832758C/en active Active
- 2011-08-08 MX MX2013011879A patent/MX341450B/es active IP Right Grant
- 2011-08-08 MY MYPI2013701917A patent/MY160432A/en unknown
- 2011-08-08 EA EA201370219A patent/EA024096B1/ru not_active IP Right Cessation
- 2011-08-08 WO PCT/KR2011/005754 patent/WO2012141385A1/en active Application Filing
- 2011-08-08 US US13/205,545 patent/US8765776B2/en active Active
- 2011-08-08 UA UAA201312969A patent/UA110244C2/ru unknown
-
2013
- 2013-10-08 CO CO13238680A patent/CO6821940A2/es not_active Application Discontinuation
- 2013-10-09 GT GT201300241A patent/GT201300241A/es unknown
- 2013-10-10 EC ECSP13012962 patent/ECSP13012962A/es unknown
- 2013-10-10 CR CR20130526A patent/CR20130526A/es unknown
- 2013-10-10 CL CL2013002905A patent/CL2013002905A1/es unknown
- 2013-10-11 ZA ZA2013/07593A patent/ZA201307593B/en unknown
- 2013-10-11 NI NI201300106A patent/NI201300106A/es unknown
- 2013-11-08 MA MA36404A patent/MA35107B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2013002905A1 (es) | 2014-04-11 |
| JP2014510785A (ja) | 2014-05-01 |
| EA024096B1 (ru) | 2016-08-31 |
| ECSP13012962A (es) | 2013-11-29 |
| EA201370219A1 (ru) | 2014-02-28 |
| CA2832758A1 (en) | 2012-10-18 |
| WO2012141385A1 (en) | 2012-10-18 |
| AU2011365756A1 (en) | 2013-10-31 |
| MA35107B1 (fr) | 2014-05-02 |
| BR112013025222B1 (pt) | 2020-03-17 |
| UA110244C2 (en) | 2015-12-10 |
| MX341450B (es) | 2016-08-19 |
| BR112013025222B8 (pt) | 2020-05-05 |
| JP5782178B2 (ja) | 2015-09-24 |
| MX2013011879A (es) | 2014-03-31 |
| CA2832758C (en) | 2015-12-15 |
| US8765776B2 (en) | 2014-07-01 |
| CO6821940A2 (es) | 2013-12-31 |
| GT201300241A (es) | 2015-08-13 |
| US20120264772A1 (en) | 2012-10-18 |
| BR112013025222A2 (pt) | 2016-12-27 |
| NI201300106A (es) | 2014-05-05 |
| AU2011365756B2 (en) | 2015-07-30 |
| CR20130526A (es) | 2014-03-11 |
| MY160432A (en) | 2017-03-15 |
| SG194162A1 (en) | 2013-11-29 |
| ZA201307593B (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141049A1 (es) | Composicion farmaceutica antihipertensiva | |
| MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
| EA201071291A2 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| MX2015001115A (es) | Derivativos de piperidina fusionados con espiro para usarse como inhibidores del canal de potasio medular externo renal. | |
| ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
| EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
| CR20150114A (es) | Composición farmacéutica recubierta que contiene regorafenib | |
| UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
| PE20142314A1 (es) | Composiciones intranasales de dexmedetomidina y metodos de uso de ellas | |
| GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| EA201291167A1 (ru) | Замещенные гетероциклилбензилпиразолы и их применение | |
| NZ608813A (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| EA201390335A1 (ru) | Введение лоркасерина индивидуумам с почечной недостаточностью | |
| EA201690679A1 (ru) | Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан | |
| EA201201109A1 (ru) | Прасугрель в тонкоизмельченной кристаллической форме и фармацевтическая композиция, содержащая его | |
| EA201390603A1 (ru) | Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин | |
| EA201190282A1 (ru) | Фармацевтическая композиция, содержащая тамсулозин | |
| CR20110674A (es) | Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del ST | |
| EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
| EA201500368A1 (ru) | Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии | |
| IN2013CH05882A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |